Cytisinicline
Cytisinicline has been studied in 2 papers since 2026: 1 trial and 1 observational study in people; 2 in the past year. The newest paper, Oct 26, 2026: “Breaking the habit: comparative effectiveness of smoking cessation therapies in a cardiovascular hospital based clinical setting”.
3 new papers in 30 daysSee all 5 papers on cytisinicline
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 10 trials, none about aging, 3 with no results posted.
“cytisinicline (OR = 3.42, 95% CI 1.23–9.48, p = 0.018) and varenicline (OR = 4.46, 95% CI 1.51–13.16, p = 0.007) significantly increased the likelihood of smoking abstinence compared to NRT”
- 1 lab in 1 country
- 10 trials, none about aging, 3 with no results posted
- 10 of 10 trials sponsored by its developers
- Human trial1
- Humans1
What is cytisinicline linked with?
1Studies link cytisinicline with smoking abstinence.
Smoking abstinence
upin humans1OR 3.42
1 study
Smoking abstinence
upin humans1OR 3.42
Cytisinicline is associated with smoking abstinence in humans (OR 3.42, 95% CI 1.23–9.48; p = 0.018).
“cytisinicline (OR = 3.42, 95% CI 1.23–9.48, p = 0.018) and varenicline (OR = 4.46, 95% CI 1.51–13.16, p = 0.007) significantly increased the likelihood of smoking abstinence compared to NRT”
HumansCompared with nicotine replacement therapy; adjusted for cardiovascular disease history, pack-years, and nicotine dependence12 weeks58% malessn = 169
ESC Congress 2026 abstract